Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.18
$0.00
$2.96
$10K-26.41250 shsN/A
HSTC
HST Global
$0.00
$0.07
$0.00
$1.05
$14K-1.47N/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
$0.00
$0.00
$0.05
$4K1.94N/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
-9.8%
$0.12
$0.01
$26.25
$14K1.49162,862 shs1,396 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%-99.95%-99.95%-99.97%
HSTC
HST Global
0.00%0.00%0.00%-99.98%-99.98%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
0.00%0.00%0.00%0.00%0.00%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%0.00%+0.91%-95.73%-99.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.18
$0.00
$2.96
$10K-26.41250 shsN/A
HSTC
HST Global
$0.00
$0.07
$0.00
$1.05
$14K-1.47N/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
$0.00
$0.00
$0.05
$4K1.94N/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
-9.8%
$0.12
$0.01
$26.25
$14K1.49162,862 shs1,396 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%-99.95%-99.95%-99.97%
HSTC
HST Global
0.00%0.00%0.00%-99.98%-99.98%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
0.00%0.00%0.00%0.00%0.00%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%0.00%+0.91%-95.73%-99.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
HSTC
HST Global
0.00
N/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
0.00
N/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.00N/A0.02N/ANaN
HSTC
HST Global
N/AN/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/A$1.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.020.00N/AN/AN/AN/AN/AN/A
HSTC
HST Global
-$150K-$0.02N/AN/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
-$15.19MN/A0.00N/AN/A-1,554.34%-338.29%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
HSTC
HST Global
N/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/A
HSTC
HST Global
N/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/A
0.13
0.13

Institutional Ownership

CompanyInstitutional Ownership
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
HSTC
HST Global
N/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
32.23%

Insider Ownership

CompanyInsider Ownership
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
31.30%
HSTC
HST Global
65.82%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
4.50%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
HSTC
HST Global
170.19 million23.99 millionNot Optionable
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
635.55 millionN/ANot Optionable
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
71.24 million4.71 millionNot Optionable

Recent News About These Companies

Virpax Pharmaceuticals Inc trading halted, news pending
Virpax receives positive Probudur results for dose range study
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur

New MarketBeat Followers Over Time

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

HST Global OTCMKTS:HSTC

$0.0002 0.00 (0.00%)
As of 09/8/2025

HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.

Sophiris Bio stock logo

Sophiris Bio OTCMKTS:SPHS

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.

Virpax Pharmaceuticals stock logo

Virpax Pharmaceuticals NASDAQ:VRPX

$0.01 0.00 (-9.76%)
As of 09/8/2025 01:34 PM Eastern

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.